Locally Advanced or Metastatic Breast Cancer Cáncer de Mama Localmente Avanzado o Metastásico MedDRA version: 9.1 Level: LLT Classification code 10055113 Term: Breast cancer metastatic
Conditions
Interventions
Trade Name: Nexavar
Pharmaceutical Form: Coated tablet
INN or Proposed INN: Sorafenib
CAS Number: 28844-1-73-1
Other descriptive name: BAY 43-9006
Concentration unit: mg milligram(s)
Concentration typ
Sponsors
SOLTI
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Histologically or cytologically confirmed adenocarcinoma of the breast. 2.Measurable or evaluable locally advanced or metastatic disease. (Locally advanced disease must not be amenable to resection with curative intent.) All scans used to document measurable or evaluable disease must be done within 4 weeks prior to randomization. 3.Age =18 years. 4.Failed taxane and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated. 5.No more than one prior chemotherapy for locally advanced or metastatic breast cancer. 6.Patients must have discontinued chemotherapy at least 3 weeks prior to randomization. 7.Prior hormonal therapy for locally advanced or metastatic disease is allowed but must be discontinued at least 3 weeks prior to randomization. 8.Prior radiation therapy is allowed but must be completed at least 3 weeks prior to randomization. Previously radiated area(s) must not be the only site of disease. 9.ECOG PS of 0 or 1 (See Appendix A). 10.Adequate bone marrow, liver, and renal function as assessed by the following: •Hemoglobin >=9.0 g/dl •Absolute neutrophil count (ANC) >=1,500/mm3 •Platelet count >=100,000/mm3 •Total bilirubin =65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1.Patients with breast cancer over-expressing human epidermal growth factor receptor 2 (HER-2) (gene amplification by fluorescence in situ hybridization (FISH) or 3+ over-expression by immunohistochemistry). Patients with unknown HER-2 status are not eligible. 2.Patients with active brain metastases. Patients with neurological symptoms must undergo a contrast computed tomography (CT) scan or magnetic resonance imaging (MRI) of the brain to exclude active brain metastasis. Patients with treated brain metastases are eligible provided they have no evidence of brain disease and are off definitive therapy (including steroids) at least 3 months prior to randomization. 3.Major surgery, open biopsy, or significant traumatic injury within 4 weeks of randomization. 4.Evidence or history of bleeding diathesis or coagulopathy. 5.Serious, non-healing wound, ulcer, or bone fracture. 6.Substance abuse, or medical, psychological, or social condition that may interfere with the patient’s participation in the study or evaluation of the study results. 7.Use of cytochrome P450 enzyme-inducing anti-epileptic drugs (such as phenytoin, carbamazepine, or phenobarbital) is not allowed. 8.Cardiac disease: •Congestive heart failure >class II New York Health Association (NYHA) (see Appendix D), or •Unstable angina (anginal symptoms at rest), or new-onset angina (began within the last 3 months), or myocardial infarction within the 6 months prior to randomization, or •Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy. 9.Uncontrolled hypertension (systolic blood pressure >150 mm Hg or diastolic pressure >90 mm Hg) despite optimal medical management. 10.Thrombolic, embolic, venous, or arterial events, such as a cerebrovascular accident including transient ischemic attacks, within the past 6 months. 11.Pulmonary hemorrhage/bleeding event >National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade 2 within 4 weeks of randomization. 12.Any other hemorrhage/bleeding event >= NCI-CTCAE Grade 3 within 4 weeks of randomization. 13.Active clinically serious infection >NCI-CTCAE Grade 2. 14.Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C. 15.Previous or concurrent cancer that is distinct in primary site or histology from breast cancer EXCEPT cervical cancer in-situ, treated basal cell carcinoma, superficial bladder tumors [Ta and Tis], or any cancer curatively treated >5 years prior to randomization. 16.Known or suspected allergy to sorafenib, or hypersensitivity to capecitabine or to any of the excipients or fluorouracil. 17.History of severe and unexpected reactions to fluoropyrimidine therapy or patients with known dihydropyrimidine dehydrogenase deficiency. 18.Prior or concurrent treatment with sorivudine or its chemically related analogues, such as brivudine. 19.Concurrent or use of St. John’s Wort or rifampin (rifampicin) within 3 weeks of randomization. 20.Prior treatment with bevacizumab or any other drugs (licensed or investigational) that target vascular endothelial growth factor (VEGF) or VEGF receptors (VEGFR). 21.Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than capecitabine and sorafenib/placebo. 22.Women who are pregnant or breast feeding. 23.Use of any investigational drug within 30 days or 5 half-lives, whichever is longer, preceding randomization.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary end point(s): The primary endpoint is Progression Free Survival (PFS);Main Objective: Primary: To compare Progression Free Survival (PFS) in patients treated with sorafenib and capecitabine versus patients treated with placebo and capecitabine for locally advanced or metastatic breast cancer.;Secondary Objective: Secondary: To compare the objective response rate, duration of response, Time To Progression (TTP) and Overall Survival (OS) of patients treated with sorafenib and capecitabine versus placebo and capecitabine. To compare the safety and tolerability of patients treated with sorafenib and capecitabine versus placebo and capecitabine. Exploratory: To compare change from baseline in Functional Assessment of Cancer Therapy–Breast Cancer (FACT-B), Version 4 (See Appendix C) score in patients treated with sorafenib and capecitabine versus patients treated with placebo and capecitabine | — |
Countries
France, Spain
Outcome results
None listed